G4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in Ganite™ (gallium nitrate injection). It targets bone tissue and is actively incorporated into bone...
- Mechanism
- Curator reviewed
G4544 reduces bone loss by inhibiting calcium resorption from bone. Preclinical evidence suggests that the mechanism of G4544 action is multifactorial and different from other current therapies used to treat bone loss, such as estrogen or selective estrogen receptor modulators (SERMs), calcitonin, or bisphosphonates (e.g., Zometa or Fosamax). G4544 preferentially accumulates in metabolically active regions of bone, inhibits osteoclast-mediated bone resorption, and favorably alters bone mineral composition and properties.
- Primary indication
- For treatment of non-Hodgkin's lymphoma, bone metastases, Paget's disease, and osteoporosisCurator reviewed
Which companies are running trials of G4544, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account